Insights on Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2029 - ResearchAndMarkets.com
The "Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
The "Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
The publisher projects that the marketplace for Type 2 Diabetes Mellitus (T2D) within the 9MM will grow from $48bn in 2019 at a compound annual growth rate (CAGR) of 6.7% to $91.9B by 2029. In particular, the publisher expects US market will contribute the most to the antidiabetic market's growth, contributing sales in $28B sales in 2019 (58% of the global antidiabetic market) and $57B in 2029 (62% of the global antidiabetic market).
New therapies entering the market will be the main drivers of growth, with recently launched GLP-1RA Rybelsus (oral semaglutide) likely to obtain a large share of the non-insulin T2D drug market and biosimilar and oral insulins likely to obtain large market share from their costly branded originators. Other major drivers for the T2D market are the increasing prevalence of obesity and the increasing prevalence of cardiovascular and kidney disease . Based on epidemiological analysis by the publisher, the number of diagnosed prevalent cases of T2D will grow by 28.76% over the forecast period, at an AGR of 2.3%, from 164,826,095 cases in 2018 to 216,029,212 cases by 2029 across the nine major pharmaceutical markets covered in this report, the US, 5EU (France, Germany, Italy, Spain and UK), Japan, India and China.
In terms of the current treatment landscape, the consensus among interviewed physicians was that they have a number of efficacious treatment options at their disposal though there are still patients that are unable to achieve optimal glycemic control, address insulin resistance and reverse or slow the decline in ?-cell function, and therefore notable unmet needs remain. KOLs interviewed by the publisher highlighted the lack of treatment options for patients with T2D and complex comorbidities, such as cardiorenal disease, remains to be an extremely important unmet need. Another major issue mentioned is the cost of insulin treatment, with a strong need for controls on insulin drug pricing and a fair price for biosimilar insulins.
In addition, drug classes across the T2D marketplace, often have poor side-effect profiles and there is an urgent need to broaden the drugs available to T2D patients to allow for safer more tailor-made therapies. Despite a number of drugs currently in development, the publisher's research suggests that the future level of attainment of these unmet needs will be modest, and a relatively high level of opportunity exists for drug developers to enter the T2D market.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global angina pectoris therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global angina pectoris market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global angina pectoris therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Topics Covered:
1 Table of Contents
2 Type 2 Diabetes (T2D): Executive Summary
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology
4.2 Pathophysiology
4.3 Symptoms
4.4 Prognosis and Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Type 2 Diabetes (2018-2028)
5.6 Discussion
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
6.5 China
6.6 India
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunities
8.1 Overview
8.2 Disease-Modifying Treatments Providing Sustained Glycemic Control
8.3 Drugs with Non-glycemic Benefits
8.4 Drugs with Improved Side-Effect Profiles
8.5 Increased Patient Compliance
8.6 Drugs for the Emergent T2D Pediatric Population
8.7 Controls on Insulin Drug Pricing and the Need for Fairly Priced Biologics
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
11 Market Outlook
11.1 Global Markets
11.2 US
11.3 5EU
11.4 Japan
11.5 China
11.6 India
12 Appendix
Companies Mentioned
- Eli Lilly
- Novo Nordisk
- Sanofi
- AstraZeneca
- Merck & Co.
- Boehringer Ingelheim
- GlaxoSmithKline
- Takeda
- Roche
- Pfizer
- Johnson & Johnson
- Novartis
- Theracos
- Lexicon Pharmaceuticals
- Hua Medicine Shanghai Ltd
- Tonghua Dongbao Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd.
- Sihuan Pharmaceutical Holdings Group Ltd
- Biocon Ltd
- Oramed Pharamceuticals
For more information about this report visit https://www.researchandmarkets.com/r/67mrn4
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005627/en/